下肢动脉疾病「手术优先」策略的适应证
该回顾性分析纳入2006年6月至2014年12月间接受股腘动脉旁路术(FPB)的241例患者共272条肢体,旨在明确哪些患者更适合首选FPB而非腔内血管重建。结果显示,跛行或腘动脉瘤患者的5年通畅率(63%)高于慢性肢体威胁性缺血(CLTI)患者(38%,P < 0.001);大隐静脉移植物、跛行或腘动脉瘤手术指征、白人种族及无慢性阻塞性肺疾病(COPD)病史是5年通畅率的独立预测因素。在白人、无COPD病史、因跛行或腘动脉瘤接受大隐静脉移植的40例FPB中,Kaplan-Meier估计5年通畅率为92%。
要点
- 跛行或腘动脉瘤患者FPB的5年通畅率为63%,高于CLTI患者的38%(P < 0.001)。
- 大隐静脉移植物、跛行或腘动脉瘤指征、白人种族及无COPD病史是5年通畅率的独立预测因素。
- 白人、无COPD病史、因跛行或腘动脉瘤接受大隐静脉移植的40例FPB,估计5年通畅率为92%。
核心结论
- 在白人、无COPD病史、拥有优质大隐静脉且因跛行或腘动脉瘤接受FPB的患者中,长期原发通畅率足以考虑将开放手术作为首选干预。
研究设计与样本
- 回顾性分析2006年6月至2014年12月间所有接受FPB的患者,排除随访不足1年的患者,共纳入241例患者272条肢体。
主要发现
- FPB指征为致残性跛行95条肢体、慢性肢体威胁性缺血148条、腘动脉瘤29条。
- 移植物类型为大隐静脉134例、人工血管126例、臂静脉8例、尸体/异种移植物4例。
- 随访5年或以上时原发通畅的旁路共97例。
- Kaplan-Meier分析显示,跛行或腘动脉瘤患者的5年通畅率为63%,高于CLTI患者的38%(P < 0.001)。
- 多变量回归分析证实大隐静脉移植物、跛行或腘动脉瘤手术指征、白人种族及无COPD病史是5年通畅率的独立预测因素;FPB构型(膝上或膝下吻合、原位或倒置大隐静脉)与5年通畅率无统计学相关性。
关键数值与推荐
- 5年通畅率:跛行或腘动脉瘤患者63% vs CLTI患者38%(P < 0.001)。
- 单变量分析中与通畅率相关的因素:使用大隐静脉移植物(P = 0.015)、跛行或腘动脉瘤手术指征(P < 0.001)、白人种族(P = 0.019)、无COPD病史(P = 0.026)。
- 白人、无COPD病史、因跛行或腘动脉瘤接受大隐静脉移植的40例FPB,Kaplan-Meier估计5年通畅率为92%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In recent years, there has been a tendency toward an "endovascular-first" approach for the treatment for femoropopliteal arterial disease. The purpose of this study is to determine if there are patients that are better served with an initial femoropopliteal bypass (FPB) rather than an endovascular attempt at revascularization. METHODS: A retrospective analysis of all patients undergoing FPB between June 2006 - December 2014 was performed. Our primary endpoint was primary graft patency, defined as patent using ultrasound or angiography without secondary intervention. Patients with <1-year follow-up were excluded. Univariate analysis of factors significant for 5-year patency was performed using χ2 tests for binary variables. A binary logistic regression analysis incorporating all factors identified as significant by univariate analysis was used to identify independent risk factors for 5-year patency. Event-free graft survival was evaluated using Kaplan-Meier models. RESULTS: We identified 241 patients undergoing FPB on 272 limbs. FPB indication was disabling claudication in 95 limbs, chronic limb-threatening ischemia (CLTI) in 148, and popliteal aneurysm in 29. In total, 134 FPB were saphenous vein grafts (SVG), 126 were prosthetic grafts, 8 were arm vein grafts, and 4 were cadaveric/xenografts. There were 97 bypasses with primary patency at 5 or more years of follow-up. Grafts patent at 5 years by Kaplan-Meier analysis were more likely to have been performed for claudication or popliteal aneurysm (63% 5-year patency) as compared with CLTI (38%, P < 0.001). Statistically significant predictors (using log rank test) of patency over time were use of SVG (P = 0.015), surgical indication of claudication or popliteal aneurysm (P < 0.001), Caucasian race (P = 0.019) and no history of COPD (P = 0.026). Multivariable regression analysis confirmed these 4 factors as significant independent predictors of 5-year patency. Of note, there was no statistical correlation between FPB configuration (above or below knee anastomosis, in-situ versus reversed saphenous vein) and 5-year patency. There were 40 FPBs in Caucasian patients without a history of COPD receiving SVG for claudication or popliteal aneurysm that had a 92% estimated 5-year patency by Kaplan-Meier survival analysis. CONCLUSIONS: Long-term primary patency that was substantial enough to consider open surgery as a first intervention was demonstrated in Caucasian patients without COPD, having good quality saphenous vein, and who underwent FPB for claudication or popliteal artery aneurysm.
引用
- Kumar M, Long GW, Rimar SD, et al. Indications for a "Surgery-First" Approach for the Treatment of Lower Extremity Arterial Disease. Ann Vasc Surg. 2023. PMID: 37023923. doi:10.1016/j.avsg.2023.03.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。